Literature DB >> 19308341

[Stroke and hypertension].

J Schrader1.   

Abstract

Arterial hypertension is the most important risk factor for stroke. Many interventional trials have unambiguously proven the benefit of antihypertensive therapy in both primary and secondary prevention for all age categories. No recommendation for any single antihypertensive substance for the primary prevention of stroke exists. Achieving the therapeutic goal (normotension) is the crucial factor. In most patients, multiple combinations of antihypertensive drugs are required to do this. For high-risk patients and in secondary prevention, substances inhibiting the renin-angiotensin-system, especially combined with calcium antagonists and indapamid, may be advantageous, while beta-blockers appear to be less well suited. In patients suffering from left-ventricular hypertrophy or atrial fibrillation, sartanes are the best-documented drug class. As TIA or stroke will often disturb the normal circadian rhythm of blood pressure and eliminate the usual night-time drop, monitoring of the therapeutic results must include ambulatory 24h measurements. The interrelation between vascular dementia and hypertension is by now also considered proven. An early start of antihypertensive treatment can prevent the development of dementia and impaired cognitive function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19308341     DOI: 10.1007/s00108-008-2291-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  High-normal blood pressure is associated with poor cognitive performance.

Authors:  Stefan Knecht; Heike Wersching; Hubertus Lohmann; Maximilian Bruchmann; Thomas Duning; Rainer Dziewas; Klaus Berger; E Bernd Ringelstein
Journal:  Hypertension       Date:  2008-02-04       Impact factor: 10.190

2.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Authors:  M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

3.  Influence of treated blood pressure on progression of silent cerebral infarction.

Authors:  T Sugiyama; J D Lee; H Shimizu; S Abe; T Ueda
Journal:  J Hypertens       Date:  1999-05       Impact factor: 4.844

4.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

5.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

6.  Reducing the risk of dementia: efficacy of long-term treatment of hypertension.

Authors:  Rita Peila; Lon R White; Kamal Masaki; Helen Petrovitch; Lenore J Launer
Journal:  Stroke       Date:  2006-04-06       Impact factor: 7.914

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial.

Authors:  Ruth Peters; Nigel Beckett; Francoise Forette; Jaakko Tuomilehto; Robert Clarke; Craig Ritchie; Adam Waldman; Ivan Walton; Ruth Poulter; Shuping Ma; Marius Comsa; Lisa Burch; Astrid Fletcher; Christopher Bulpitt
Journal:  Lancet Neurol       Date:  2008-07-07       Impact factor: 44.182

9.  A population-based study on blood pressure and brain atrophy in 85-year-olds.

Authors:  I Skoog; L A Andreasson; S Landahl; B Lernfelt
Journal:  Hypertension       Date:  1998-09       Impact factor: 10.190

10.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

View more
  2 in total

1.  Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria.

Authors:  Nnamani Nnenna Adaeze; Anthony Uchenna Emeribe; Idris Abdullahi Nasiru; Adamu Babayo; Emmanuel K Uko
Journal:  Adv Hematol       Date:  2014-11-16

2.  Geometric Features of the Pial Arteriolar Networks in Spontaneous Hypertensive Rats: A Crucial Aspect Underlying the Blood Flow Regulation.

Authors:  Dominga Lapi; Martina Di Maro; Nicola Serao; Martina Chiurazzi; Maurizio Varanini; Lina Sabatino; Rossana Scuri; Antonio Colantuoni; Bruna Guida
Journal:  Front Physiol       Date:  2021-07-05       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.